ArticleFrontiers in immunology2026
A combined immune-nutritional score as a prognostic indicator in neoadjuvant-treated esophageal squamous cell carcinoma.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Reliable biomarkers that predict treatment response and long-term outcomes in neoadjuvant-treated esophageal squamous cell carcinoma (ESCC) remain limited. The Gustave Roussy Immune (GRIm) score and the Controlling Nutritional Status (CONUT) score respectively reflect systemic inflammation and nutritional status. This study evaluated whether integrating these indices (GRIm-CONUT) improves prognostic prediction in ESCC. Methods: We retrospectively analyzed 216 patients with resectable ESCC who received neoadjuvant chemotherapy, chemoradiotherapy, or chemoimmunotherapy followed by curative (R0) esophagectomy between June 2016 and December 2021. GRIm and CONUT scores were calculated from pre-treatment laboratory parameters, and patients were classified into three GRIm-CONUT categories (0, 1, 2). Logistic regression identified independent predictors of pathological complete response (pCR). Overall survival (OS) and recurrence-free survival (RFS) were assessed using Kaplan-Meier and Cox proportional hazards models. A nomogram incorporating GRIm-CONUT and ypTNM staging was developed and validated using bootstrap resampling. Results: Higher GRIm-CONUT scores were significantly associated with lower pCR rates (p < 0.01) and poorer OS and RFS (all p < 0.001). Multivariate logistic regression confirmed GRIm-CONUT score, cN stage, and neoadjuvant regimen as independent predictors of pCR. In multivariate Cox analysis, GRIm-CONUT and ypN stage remained independent predictors of OS, while GRIm-CONUT, ypT stage, and ypN stage independently predicted RFS. A GRIm-CONUT-based nomogram demonstrated superior discrimination (C-index 0.717 vs. 0.659 for ypTNM) and offered greater clinical net benefit in decision-curve analysis. Conclusions: The GRIm-CONUT composite score is an independent predictor of pCR, OS, and RFS in ESCC patients undergoing neoadjuvant therapy and surgery. As an inexpensive and readily obtainable biomarker, it enables more accurate prognostic stratification and may support personalized perioperative management. Prospective multicenter validation is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.